Based on the Glenmark Pharmaceuticals Limited stock forecast from 4 analysts, the average analyst target price for Glenmark Pharmaceuticals Limited is INR 1,740.60 over the next 12 months. Glenmark Pharmaceuticals Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Glenmark Pharmaceuticals Limited is Bearish, which is based on 2 positive signals and 9 negative signals. At the last closing, Glenmark Pharmaceuticals Limited’s stock price was INR 1,540.15. Glenmark Pharmaceuticals Limited’s stock price has changed by +5.98% over the past week, -3.34% over the past month and +82.68% over the last year.
No recent analyst target price found for Glenmark Pharmaceuticals Limited
No recent average analyst rating found for Glenmark Pharmaceuticals Limited
Company Overview Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India. Read Less
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulat...Read More
Frequently Asked Questions About Glenmark Pharmaceuticals Limited (GLENMARK:NSE) Stock
Based on ratings from 4 analysts Glenmark Pharmaceuticals Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, 1 sell and hold ratings.
GLENMARK:NSE stock's dividend yield is 0.16%.
Our analysis grades GLENMARK:NSE stock's dividend yield at F. This means that GLENMARK:NSE stock's dividend yield is above 10% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this GLENMARK:NSE may be a poor dividend stock for its sector.
Based on targets from 4 analysts, the average taret price for GLENMARK:NSE is INR 1,740.60 over the next 12 months. The maximum analyst target price is INR 1894 while the minimum anlayst target price is INR 1345.
GLENMARK:NSE stock's Price/Earning ratio is 85.04.
Our analysis grades GLENMARK:NSE stock's Price / Earning ratio at F. This means that GLENMARK:NSE stock's Price/Earning ratio is above 78% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this GLENMARK:NSE may be a overvalued for its sector.
The last closing price of GLENMARK:NSE's stock was INR 1,540.15.
The most recent market capitalization for GLENMARK:NSE is INR 395.18B.
Based on targets from 4 analysts, the average taret price for GLENMARK:NSE is projected at INR 1,740.60 over the next 12 months.
This means that GLENMARK:NSE's stock price may go up by +13.01% over the next 12 months.
We can't find any ETFs which contains Glenmark Pharmaceuticals Limited's stock.
As per our most recent records Glenmark Pharmaceuticals Limited has 14,989 Employees.
Glenmark Pharmaceuticals Limited's registered address is Glenmark House, Mumbai, India, 400099.
You can get more information about it from Glenmark Pharmaceuticals Limited's website at https://www.glenmarkpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Glenmark Pharmaceuticals Limited (GLENMARK:NSE) Stock
Based on ratings from 4 analysts Glenmark Pharmaceuticals Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, 1 sell and hold ratings.
GLENMARK:NSE stock's dividend yield is 0.16%.
Our analysis grades GLENMARK:NSE stock's dividend yield at F. This means that GLENMARK:NSE stock's dividend yield is above 10% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this GLENMARK:NSE may be a poor dividend stock for its sector.
Based on targets from 4 analysts, the average taret price for GLENMARK:NSE is INR 1,740.60 over the next 12 months. The maximum analyst target price is INR 1894 while the minimum anlayst target price is INR 1345.
GLENMARK:NSE stock's Price/Earning ratio is 85.04.
Our analysis grades GLENMARK:NSE stock's Price / Earning ratio at F. This means that GLENMARK:NSE stock's Price/Earning ratio is above 78% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this GLENMARK:NSE may be a overvalued for its sector.
The last closing price of GLENMARK:NSE's stock was INR 1,540.15.
The most recent market capitalization for GLENMARK:NSE is INR 395.18B.
Based on targets from 4 analysts, the average taret price for GLENMARK:NSE is projected at INR 1,740.60 over the next 12 months.
This means that GLENMARK:NSE's stock price may go up by +13.01% over the next 12 months.
We can't find any ETFs which contains Glenmark Pharmaceuticals Limited's stock.
As per our most recent records Glenmark Pharmaceuticals Limited has 14,989 Employees.
Glenmark Pharmaceuticals Limited's registered address is Glenmark House, Mumbai, India, 400099.
You can get more information about it from Glenmark Pharmaceuticals Limited's website at https://www.glenmarkpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GLENMARK:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
